Crossmark

Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy

Crossref DOI link: https://doi.org/10.15252/emmm.201404827

Published Online: 2015-06-15

Published Print: 2015-08-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Miller, Bryan W

Morton, Jennifer P

Pinese, Mark

Saturno, Grazia

Jamieson, Nigel B

McGhee, Ewan

Timpson, Paul

Leach, Joshua

McGarry, Lynn

Shanks, Emma

Bailey, Peter

Chang, David

Oien, Karin

Karim, Saadia

Au, Amy

Steele, Colin

Carter, Christopher Ross

McKay, Colin

Anderson, Kurt

Evans, Thomas R Jeffry

Marais, Richard

Springer, Caroline

Biankin, Andrew

Erler, Janine T

Sansom, Owen J
Funding

Funding for this research was provided by:

Novo Nordisk Foundation

Cancer Research UK

Pancreatic Cancer Research Fund
License Information

Text and Data Mining valid from 2015-06-15

Version of Record valid from 2015-06-15
More Information

Article History

Received: 9 November 2014

Revised: 12 May 2015

Accepted: 21 May 2015

First Online: 15 June 2015

Conflict of interest

: The authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below